NO20081811L - Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt - Google Patents

Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt

Info

Publication number
NO20081811L
NO20081811L NO20081811A NO20081811A NO20081811L NO 20081811 L NO20081811 L NO 20081811L NO 20081811 A NO20081811 A NO 20081811A NO 20081811 A NO20081811 A NO 20081811A NO 20081811 L NO20081811 L NO 20081811L
Authority
NO
Norway
Prior art keywords
combination drug
drug containing
combination
cerebral infarction
probucol
Prior art date
Application number
NO20081811A
Other languages
English (en)
Inventor
Ki Whan Hong
Tomohiro Yoshikawa
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of NO20081811L publication Critical patent/NO20081811L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Biochemistry (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Oppfinnelsen angår et kombinasjonslegemiddel omfattende en kombinasjon av et tetrazolylalkoksy-dihydrokarbostyrilderivat av formelen: hvori R er sykloalkyl, A er lavere alkylen, og bindingen mellom 3- og 4-stillingene av karbostyrilkjernen er en enkeltbinding eller dobbeltbinding, eller et salt derav, og probukol, som er anvendbar for forhindring og behandling av cerebralt infarkt innbefattende akutt, cerebralt infarkt og kronisk cerebralt infarkt, arteriosklerose, nyresykdommer (for eksempel diabetisk nefropati, nyresvikt, nefritt), og diabetes på grunn av synergistisk superoksidundertrykkende effekt av kom-binasjonen.
NO20081811A 2005-09-15 2008-04-14 Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt NO20081811L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US71695405P 2005-09-15 2005-09-15
US76177506P 2006-01-25 2006-01-25
PCT/JP2006/318675 WO2007032557A1 (en) 2005-09-15 2006-09-14 Combination drug containing probucol and a tetrazolylalkoxy-dihydrocarbostyril derivative with superoxide supressant effects

Publications (1)

Publication Number Publication Date
NO20081811L true NO20081811L (no) 2008-04-14

Family

ID=37420867

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20081811A NO20081811L (no) 2005-09-15 2008-04-14 Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt

Country Status (21)

Country Link
US (2) US8580818B2 (no)
EP (2) EP1942895B1 (no)
JP (2) JP5179354B2 (no)
KR (1) KR101299320B1 (no)
AR (1) AR057520A1 (no)
AU (1) AU2006289752B2 (no)
BR (1) BRPI0616223A2 (no)
CA (1) CA2620296C (no)
CY (1) CY1112716T1 (no)
DK (1) DK1942895T3 (no)
ES (1) ES2378896T3 (no)
HK (1) HK1122996A1 (no)
IL (1) IL189751A0 (no)
MY (1) MY145787A (no)
NO (1) NO20081811L (no)
PL (1) PL1942895T3 (no)
PT (1) PT1942895E (no)
RU (1) RU2411945C2 (no)
SG (1) SG165379A1 (no)
TW (1) TWI372053B (no)
WO (1) WO2007032557A1 (no)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR065588A1 (es) * 2007-03-09 2009-06-17 Otsuka Pharma Co Ltd Un medicamento para tratar enfermedad pulmonar obstructiva cronica
AR070816A1 (es) * 2008-03-14 2010-05-05 Otsuka Pharma Co Ltd Farmaco de combinacion para tratar trastornos vasculares

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS5535019A (en) * 1978-09-01 1980-03-11 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
JPH04193836A (ja) 1990-11-26 1992-07-13 Banyu Pharmaceut Co Ltd 抗高脂血症剤
JPH107590A (ja) 1996-06-24 1998-01-13 Chugai Pharmaceut Co Ltd 脳循環障害後遺症または脳虚血後の脳神経障害の治療剤
FR2751540B1 (fr) * 1996-07-26 1998-10-16 Sanofi Sa Composition pharmaceutique antithrombotique
CA2265827A1 (en) 1996-09-18 1998-03-26 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardiovascular disease
US6245797B1 (en) * 1997-10-22 2001-06-12 Merck & Co., Inc. Combination therapy for reducing the risks associated with cardio-and-cerebrovascular disease
WO1999024400A1 (en) * 1997-11-10 1999-05-20 Vyrex Corporation Probucol esters and uses thereof
US6235311B1 (en) * 1998-03-18 2001-05-22 Bristol-Myers Squibb Company Pharmaceutical composition containing a combination of a statin and aspirin and method
AU5965399A (en) 1998-10-12 2000-05-01 Andreas Bockelmann Pharmaceutically active composition
DK1272220T4 (en) 2000-04-10 2016-11-28 Nicholas John Wald Cardiovascular disease prevention formulation
US20020115728A1 (en) * 2000-09-05 2002-08-22 Roland Stocker Compositions and methods for treating cardiovascular disorders
WO2002058731A2 (en) * 2001-01-26 2002-08-01 Schering Corporation Combinations of sterol absorption inhibitor(s) with cardiovascular agent(s) for the treatment of vascular conditions
US6576256B2 (en) * 2001-08-28 2003-06-10 The Brigham And Women's Hospital, Inc. Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin
JP2003192573A (ja) * 2001-12-25 2003-07-09 Otsuka Pharmaceut Factory Inc 経口ゲル製剤
US20030181461A1 (en) * 2002-01-25 2003-09-25 Lautt Wilfred Wayne Use of phosphodiesterase antagonists to treat insulin resistance
US6743806B2 (en) * 2002-10-23 2004-06-01 Otsuka Pharmaceutical Company, Limited Active oxygen scavenger
JP2005232059A (ja) 2004-02-18 2005-09-02 Iichiro Shimomura 低アディポネクチン血症予防・治療剤
PT1894576E (pt) 2005-06-08 2011-07-29 Kowa Co Novo agente redutor dos níveis de triglicéridos
JP4193836B2 (ja) 2005-10-24 2008-12-10 ブラザー工業株式会社 インク噴射装置の製造方法

Also Published As

Publication number Publication date
US20090176826A1 (en) 2009-07-09
AU2006289752A1 (en) 2007-03-22
SG165379A1 (en) 2010-10-28
RU2008114512A (ru) 2009-10-20
US8580818B2 (en) 2013-11-12
US20140045889A1 (en) 2014-02-13
EP1942895B1 (en) 2012-02-01
HK1122996A1 (en) 2009-06-05
JP5603393B2 (ja) 2014-10-08
DK1942895T3 (da) 2012-03-05
EP1942895A1 (en) 2008-07-16
IL189751A0 (en) 2008-12-29
KR20080049822A (ko) 2008-06-04
PT1942895E (pt) 2012-03-29
MY145787A (en) 2012-04-30
CA2620296C (en) 2013-10-22
PL1942895T3 (pl) 2012-07-31
BRPI0616223A2 (pt) 2011-06-14
TW200744597A (en) 2007-12-16
CA2620296A1 (en) 2007-03-22
RU2411945C2 (ru) 2011-02-20
CY1112716T1 (el) 2016-02-10
EP2275106A1 (en) 2011-01-19
AR057520A1 (es) 2007-12-05
TWI372053B (en) 2012-09-11
JP2009508804A (ja) 2009-03-05
ES2378896T3 (es) 2012-04-18
AU2006289752B2 (en) 2011-06-09
WO2007032557A1 (en) 2007-03-22
KR101299320B1 (ko) 2013-09-03
JP2013014605A (ja) 2013-01-24
JP5179354B2 (ja) 2013-04-10

Similar Documents

Publication Publication Date Title
WO2008127682A3 (en) Combination anticoagulant therapy with a compound that acts as a factor xa inhibitor
NO20083026L (no) Terapeutisk middel for diabetes
LTC1869025I2 (lt) Piperazinu pakeisti benzotiofenai, skirti psichikos sutrikimų gydymui
WO2009134973A8 (en) Quinolines and related analogs as sirtuin modulators
NO20092374L (no) Forbindelser som har bade angiotensin II receptorantagonisme og PPARy aktiverende aktiviteter
HRP20141248T1 (en) 4-(indol-7-ylcarbonylaminomethyl)cyclohexanecarboxylic acid derivatives as ep4 receptor antagonists useful for the treatment of chronic renal failure or diabetic nephropathy
IL194831A (en) Components for influencing the movement of contaminants, body fluids or other entities and / or influencing other physiological conditions
WO2006094237A3 (en) Acridine and quinoline dervatives as sirtuin modulators
WO2010075861A3 (en) Methods of identifying critically ill patients at increased risk of development of organ failure and compounds for the treatment hereof
WO2008097428A3 (en) Compounds and compositions as modulators of gpr119 activity
EP2344475A4 (en) QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE
MX2010004965A (es) Derivados de amida como moduladores de la sirtuina.
BR122021002201A8 (pt) Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
WO2009055331A3 (en) Bicyclic heterocycle derivatives and their use as modulators of the activity of gpr119
ATE476422T1 (de) Substituierte 2-aminoalkylthio-benzimidazole und ihre verwendung zur blutzuckersenkung
NO20082497L (no) Diarylureaer for behandling av pulmonal hypertensjon
WO2009121939A3 (en) C-aryl glycoside compounds for the treatment of diabetes and obesity
BR112012032813A2 (pt) composto, composição farmacêutica, e, método para prevenir, tratar ou melhorar uma doença ou condição.
WO2009068659A3 (en) Novel disease treatment by predicting drug association
EP1950209A4 (en) TREATMENT AGENT FOR CIRCULATORY INSUFFICIENCY
NO20081811L (no) Kombinasjonslegemiddel inneholdende probucol og et tetrazolylalkoksy-dihydrokarbostyrilderivat med superoksid-undertrykkende effekt
WO2009066299A3 (en) Use of haptoglobin genotyping in diagnosis and treatment of cardiovascular disease
EA201171125A1 (ru) Антагонист минералокортикоидного рецептора и способы его применения
WO2008152068A3 (en) [1,10]-phenanthroline derivatives for the treatment of neurodegenerative or haematological diseases
MX2010014441A (es) Diaril ureas para tratar la insuficiencia cardiaca.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application